Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2017-01-24028,2017,Fernandes 2017 BMC Musculoskelet Disord,Cost-Saving,"Supervised pre-surgical neuromuscular exercise program and preoperative educational package VERSUS Standard/Usual Care- Preoperative educational package IN Specific disease- Hip or knee osteoarthritis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.",28061841,"Specific disease- Hip or knee osteoarthritis; Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.",Supervised pre-surgical neuromuscular exercise program and preoperative educational package,Supervised neuromuscular exercise prior to hip and knee replacement: 12-month clinical effect and cost-utility analysis alongside a randomised controlled trial.,Standard/Usual Care- Preoperative educational package,SE
2017-01-23937,2017,Jensen 2017 Pain,32000,"Multifaceted guideline implementation VERSUS Standard/Usual Care- Usual implementation strategy IN Specific disease- Low back pain; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark.",28114182,"Specific disease- Low back pain; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark.",Multifaceted guideline implementation,Economic evaluation of an implementation strategy for the management of low back  pain in general practice.,Standard/Usual Care- Usual implementation strategy,SW
2017-01-23925,2017,Hansen 2017 Eur J Prev Cardiol,3.8e+006,Cardiac rehabilitation VERSUS None IN Specific disease- Ischaemic heart disease and heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- patients with heart valve surgery.,28121172,Specific disease- Ischaemic heart disease and heart failure; Age- Adult; Gender- Both; Country- Denmark; Other- patients with heart valve surgery.,Cardiac rehabilitation,Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care.,None,SW
2017-01-23822,2017,Schroder 2017 J Psychosom Res,39000,"Cognitive behavioral group treatment VERSUS Enhanced standard/usual care IN Specific disease- Functional somatic syndromes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark; Other- Multiple symptoms for at least 2 years.",28183406,"Specific disease- Functional somatic syndromes; Age- 19 to 40 years, 41 to 64 years; Gender- Both; Country- Denmark; Other- Multiple symptoms for at least 2 years.",Cognitive behavioral group treatment,Long-term economic evaluation of cognitive-behavioural group treatment versus enhanced usual care for functional somatic syndromes.,Enhanced standard/usual care,NE
2017-01-23443,2017,Dijkstra 2017 BJU Int,Cost-Saving,patients with elevated PSA level (>3 ng/mL) undergo SelectMDx text followed by a systematic TRUS-guided biopsy if positive VERSUS Standard/Usual Care- patients with elevated PSA level (>3 ng/mL) undergo a systematic TRUS-guided biopsy IN Healthy; Age- Adult; Gender- Male; Country- Denmark; Other- Men with an elevated prostate-specific antigen level (>3 ng/mL).,28370948,Healthy; Age- Adult; Gender- Male; Country- Denmark; Other- Men with an elevated prostate-specific antigen level (>3 ng/mL).,patients with elevated PSA level (>3 ng/mL) undergo SelectMDx text followed by a systematic TRUS-guided biopsy if positive,Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.,Standard/Usual Care- patients with elevated PSA level (>3 ng/mL) undergo a systematic TRUS-guided biopsy,SE
2017-01-23314,2017,Roze 2017 Diabetes Res Clin Pract,15000,Sensor-augmented pump therapy and low glucose suspend VERSUS Standard/Usual Care- Continuous subcutaneous insulin infusion IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Increased risk for hypoglycemia cohort.,28432898,Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Increased risk for hypoglycemia cohort.,Sensor-augmented pump therapy and low glucose suspend,Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump  therapy in patients with type 1 diabetes in Denmark.,Standard/Usual Care- Continuous subcutaneous insulin infusion,NE
2017-01-23314,2017,Roze 2017 Diabetes Res Clin Pract,25000,Sensor-augmented pump therapy and low glucose suspend VERSUS Continuous subcutaneous insulin infusion IN Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Hyperglycemic.,28432898,Specific disease- Type 1 diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Hyperglycemic.,Sensor-augmented pump therapy and low glucose suspend,Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump  therapy in patients with type 1 diabetes in Denmark.,Continuous subcutaneous insulin infusion,NE
2017-01-23218,2017,Klinge 2017 J Neurogastroenterol Motil,810,Gastric electrical stimulation VERSUS None IN Specific disease- Nausea and vomiting; Age- Adult; Gender- Both; Country- Denmark; Other- Type 1 and 2 diabetes patients with severe recurrent nausea and vomiting.,28478663,Specific disease- Nausea and vomiting; Age- Adult; Gender- Both; Country- Denmark; Other- Type 1 and 2 diabetes patients with severe recurrent nausea and vomiting.,Gastric electrical stimulation,Early Assessment of Cost-effectiveness of Gastric Electrical Stimulation for Diabetic Nausea and Vomiting.,None,NE
2017-01-23133,2017,Witt Udsen 2017 BMJ Open,80000,Set of telehealthcare equipment and monitering by municipality-based healthcare team in addition to usual care VERSUS Standard/Usual Care IN Specific disease- Chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Denmark.,28515193,Specific disease- Chronic obstructive pulmonary disease; Age- Adult; Gender- Both; Country- Denmark.,Set of telehealthcare equipment and monitering by municipality-based healthcare team in addition to usual care,Cost-effectiveness of telehealthcare to patients with chronic obstructive pulmonary disease: results from the Danish ''TeleCare North'' cluster-randomised trial.,Standard/Usual Care,NE
2016-01-22716,2016,Pedersen-Bjergaard 2016 Curr Med Res Opin,4500,"Insulin analogue (insulin detemir and insulin aspart) VERSUS Human insulin (neutral protamine Hagedorn [NPH] insulin and regular insulin) IN Specific disease- Type I diabetes mellitus (TIDM); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Prone to recurrent severe hypoglycemia.",27326862,"Specific disease- Type I diabetes mellitus (TIDM); Age- 0 to 18 years, 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Prone to recurrent severe hypoglycemia.",Insulin analogue (insulin detemir and insulin aspart),Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia.,Human insulin (neutral protamine Hagedorn [NPH] insulin and regular insulin),NE
2016-01-22307,2016,Evans 2016 Diabetes Ther,13000,"Insulin Degludec/Insulin Aspart (IDegAsp) VERSUS Biphasic Insulin Aspart (BIAsp 30) IN Specific disease- Type 2 Diabetes Mellitus (T2DM); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.",27553066,"Specific disease- type 2 diabetes (T2DM); Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark.",Insulin Degludec/Insulin Aspart (IDegAsp),Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.,Biphasic Insulin Aspart (BIAsp 30),NE
2016-01-22003,2016,Pollock                          2016 J Med Econ,35000,Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-bolus regimen.,27705031,Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-bolus regimen.,Insulin degludec,A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.,Insulin glargine,NE
2016-01-22003,2016,Pollock                          2016 J Med Econ,Cost-Saving,Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 1 diabetes on a basal-bolus regimen.,27705031,Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 1 diabetes on a basal-bolus regimen.,Insulin degludec,A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.,Insulin glargine,SE
2016-01-22003,2016,Pollock                          2016 J Med Econ,Cost-Saving,Insulin degludec VERSUS Insulin glargine IN Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-only regimen.,27705031,Specific disease- Diabetes; Age- Adult; Gender- Both; Country- Denmark; Other- Patients with type 2 diabetes on a basal-only regimen.,Insulin degludec,A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.,Insulin glargine,SE
2016-01-19643,2016,Joergensen 2016 Pancreatology,55000,"Annual endoscopic ultrasonography and carbohydrate antigen 19-9 (CA19-9) screening VERSUS Standard/Usual Care IN Specific disease- patients with hereditary pancreatitis or with a disposition of hereditary pancreatitis and first-degree relative of patients with familial pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Only patients who could endure a pancreatic resection were included..",27090585,"Specific disease- patients with hereditary pancreatitis or with a disposition of hereditary pancreatitis and first-degree relative of patients with familial pancreatic cancer; Age- 19 to 40 years, 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Only patients who could endure a pancreatic resection were included..",Annual endoscopic ultrasonography and carbohydrate antigen 19-9 (CA19-9) screening,Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.,Standard/Usual Care,NE
2015-01-18687,2015,Olsen 2015 Cost Eff Resour Alloc,5300,Persistent human papillomavirus (HPV) vaccination VERSUS Screening alone IN Healthy; Age- 0 to 18 years; Gender- Female; Country- Denmark.,25694771,Healthy; Age- 0 to 18 years; Gender- Female; Country- Denmark.,Persistent human papillomavirus (HPV) vaccination,Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males  and females.,Screening alone,NE
2015-01-18687,2015,Olsen 2015 Cost Eff Resour Alloc,61000,Persistent human papillomavirus (HPV) vaccination for boys and girls VERSUS Persistent human papillomavirus (HPV) vaccination for 12-year-old girls only IN Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.,25694771,Healthy; Age- 0 to 18 years; Gender- Both; Country- Denmark.,Persistent human papillomavirus (HPV) vaccination for boys and girls,Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males  and females.,Persistent human papillomavirus (HPV) vaccination for 12-year-old girls only,NE
2015-01-16546,2015,Sabale 2015 Prim Care Diabetes,12000,"Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Average duration of diabetes is 6 years and 18% are smokers.",24840612,"Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Denmark; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin",Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.,Sulfonylurea (SU) added to metformin,NE
2015-01-16546,2015,Sabale 2015 Prim Care Diabetes,7000,"Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Oral sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Norway; Other- Average duration of diabetes is 6 years and 18% are smokers.",24840612,"Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Norway; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin",Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.,Oral sulfonylurea (SU) added to metformin,NE
2015-01-16546,2015,Sabale 2015 Prim Care Diabetes,8000,"Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin VERSUS Oral sulfonylurea (SU) added to metformin IN Specific disease- Type 2 diabetes mellitus; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- Average duration of diabetes is 6 years and 18% are smokers.",24840612,"Specific disease- type 2 diabetes; Age- 41 to 64 years, >=65 years; Gender- Both; Country- Finland; Other- Average duration of diabetes is 6 years and 18% are smokers.","Dapagliflozin (Forxiga), a class of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for the oral treatment of T2DM, added to metformin",Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.,Oral sulfonylurea (SU) added to metformin,NE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
